-
公开(公告)号：WO02055059A3
公开(公告)日：2002-09-06
申请号：PCT/US0149737
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51
CPC classification number: A61K31/495 , A61K9/10 , A61K9/14 , A61K9/145 , A61K9/146 , A61K9/1688 , A61K31/496
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of : (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution ; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound ; and (iii) seeding the first solution or the second solvent or the presuspension.
Abstract translation: 本发明提供了制备药物活性化合物的悬浮液的方法，所述药物活性化合物在水混溶性第一有机溶剂中的溶解度大于含水第二溶剂中的溶解度。 该方法包括以下步骤：（i）将第一数量的药学活性化合物溶解在可与水混溶的第一有机溶剂中以形成第一溶液; （ii）将第一溶液与第二溶剂混合以沉淀药物活性化合物; 和（iii）接种第一溶液或第二溶剂或预悬浮液。
-
2.发明申请PREPARATION OF SUBMICRON SIZED NANOPARTICLES VIA DISPERSION AND SOLVENT OR LIQUID PHASE REMOVAL 审中-公开通过分散和溶剂或液相去除来制备亚硫酸钠纳米颗粒
公开(公告)号：WO03026611A3
公开(公告)日：2003-07-03
申请号：PCT/US0230447
申请日：2002-09-25
Applicant: BAXTER INT
Inventor： BRYNJELSEN SEAN , STERNBERG SHMUEL , DUNHAM ANDREW J , DOTY MARK J , KIPP JAMES E , JAYSWAL NAILESH , NARAYANAN KRISHNASWAMY
IPC: A61K9/14 , A61K9/19 , A61K9/51 , A61K31/496 , A61K45/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , B01J13/04
CPC classification number: A61K9/14 , A61K9/145 , A61K9/5169 , A61K9/5192 , B01J13/04
Abstract: The present invention relates to a process for preparing submicron sized nanoparticles of a poorly water soluble compound by sonicating to evaporate a portion of the organic phase or by lyophilizing a dispersion or microdispersion of a multiphase system having an organic phase and an aqueous phase, the organic phase havingthe poorly water soluble organic compound therein. The method is preferably used to prepare nanoparticles of a poorly water soluble, pharmaceutically active compound suitable for in vivo delivery, particularly by parenteral routes.
Abstract translation: 本发明涉及通过超声处理以蒸发一部分有机相或通过冻干具有有机相和水相的多相体系的分散体或微分散体来制备难溶于水的化合物的亚微米尺寸的纳米颗粒的方法，所述有机相和水相的有机相 相中其水溶性差的有机化合物。 该方法优选用于制备适于体内递送的水溶性差的药学活性化合物的纳米颗粒，特别是通过肠胃外途径。
-
公开(公告)号：DE60234618D1
公开(公告)日：2010-01-14
申请号：DE60234618
申请日：2002-10-18
Applicant: BAXTER INT
Inventor： KIPP JAMES E , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , KONKEL JAMIE TERESA
IPC: A61K9/10 , A61K8/02 , A61K8/04 , A61K8/06 , A61K8/34 , A61K8/35 , A61K8/36 , A61K8/365 , A61K8/37 , A61K8/39 , A61K8/40 , A61K8/41 , A61K8/44 , A61K8/46 , A61K8/60 , A61K8/64 , A61K8/73 , A61K8/86 , A61K8/89 , A61K8/891 , A61K9/107 , A61K9/14 , A61K31/12 , A61K31/4985 , A61K31/58 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44 , A61K47/46 , A61Q19/00
Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.
-
公开(公告)号：DE60117873T2
公开(公告)日：2006-08-24
申请号：DE60117873
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP E , WONG CHUNG , DOTY J , REBBECK L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
IPC: A61K9/20 , C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K9/51 , A61K31/192 , A61K31/495 , A61K31/496 , A61K31/55 , A61K31/573 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10
-
公开(公告)号：AT319432T
公开(公告)日：2006-03-15
申请号：AT01998077
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51 , A61K31/192 , A61K31/55 , A61K31/573
-
Patent Agency Ranking
公开(公告)号：NO20032860D0
公开(公告)日：2003-06-20
申请号：NO20032860
申请日：2003-06-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
-
公开(公告)号：CA2431705A1
公开(公告)日：2002-07-18
申请号：CA2431705
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： BRYNJELSEN SEAN , WERLING JANE , REBBECK CHRISTINE L , DOTY MARK J , SRIRAM RAJARAM , KIPP JAMES E , WONG JOSEPH CHUNG TAK
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51
Abstract: The present invention provides a method for preparing a suspension of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first organic solvent than in a second solvent which is aqueous. The process includes the steps of : (i) dissolving a first quantity of the pharmaceutically-active compound in the water-miscible first organic solvent to form a first solution ; (ii) mixing the first solution with the second solvent to precipitate the pharmaceutically-active compound ; and (ii i) seeding the first solution or the second solvent or the presuspension.
-
公开(公告)号：AT450250T
公开(公告)日：2009-12-15
申请号：AT02773797
申请日：2002-10-18
Applicant: BAXTER INT
Inventor： KIPP JAMES , DOTY MARK , REBBECK CHRISTINE , BRYNJELSEN SEAN , KONKEL JAMIE
IPC: A61K9/10 , A61K8/02 , A61K8/04 , A61K8/06 , A61K8/34 , A61K8/35 , A61K8/36 , A61K8/365 , A61K8/37 , A61K8/39 , A61K8/40 , A61K8/41 , A61K8/44 , A61K8/46 , A61K8/60 , A61K8/64 , A61K8/73 , A61K8/86 , A61K8/89 , A61K8/891 , A61K9/107 , A61K9/14 , A61K31/12 , A61K31/4985 , A61K31/58 , A61K47/02 , A61K47/06 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/16 , A61K47/18 , A61K47/20 , A61K47/26 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61K47/44 , A61K47/46 , A61Q19/00
Abstract: The present invention discloses a composition of a stable suspension of a poorly water soluble pharmaceutical agent or cosmetic in the form of particles of the pharmaceutical agent or cosmetic suspended in a frozen aqueous matrix and method for its preparation. The composition is stable for a prolonged period of time, preferably six months or longer and is suitable for parenteral, oral, or non-oral routes such as pulmonary (inhalation), ophthalmic, or topical administration.
-
9.发明专利
公开(公告)号：AU2002337692B2
公开(公告)日：2007-09-13
申请号：AU2002337692
申请日：2002-09-25
Applicant: BAXTER INT
Inventor： DUNHAM ANDREW J , BRYNJELSEN SEAN , JAYSWAL NAILESH , DOTY MARK J , NARAYANAN KRISHNASWAMY , STERNBERG SHMUEL , KIPP JAMES E
IPC: A61K9/14 , A61K9/19 , A61K9/51 , A61K31/496 , A61K45/00 , A61K47/10 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/32 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , B01J13/04
Abstract: The present invention relates to a process for preparing submicron sized nanoparticles of a poorly water soluble compound by lyophilizing a dispersion or microdispersion of a multiphase system having an organic phase and an aqueous phase, the organic phase having the poorly water soluble organic compound therein. The method is preferably used to prepare nanoparticles of a poorly water soluble, pharmaceutically active compound suitable for in vivo delivery, particularly by parenteral routes.
-
公开(公告)号：NZ526608A
公开(公告)日：2006-06-30
申请号：NZ52660801
申请日：2001-12-20
Applicant: BAXTER INT
Inventor： KIPP JAMES E , WONG JOSEPH CHUNG TAK , DOTY MARK J , REBBECK CHRISTINE L , BRYNJELSEN SEAN , WERLING JANE , SRIRAM RAJARAM
IPC: C07D407/14 , A61K9/10 , A61K9/14 , A61K9/16 , A61K31/495 , A61K31/496 , A61K47/12 , A61K47/14 , A61K47/18 , A61K47/20 , A61K47/24 , A61K47/28 , A61K47/34 , A61K47/36 , A61K47/38 , A61K47/42 , A61P31/10 , A61K9/20 , A61K9/51
Abstract: A method for preparing submicron sized particles of a pharmaceutically-active compound, the solubility of which is greater in a water-miscible first solvent than in a second solvent which is aqueous is disclosed, wherein the process comprises the steps of: (i) dissolving the pharmaceutically-active compound in the water-miscible first solvent to form a solution, the first solvent being selected from the group consisting of N methyl-2-pyrrolidinone, 2-pyrrolidone, dimethyl sulfoxide, dimethylacetamide, lactic acid, methanol, ethanol, isopropanol, 3-pentanol, n-propanol, glycerol, butylene glycol, ethylene glycol, polypropylene glycol, mono- and diacylated monoglycerides, dimethyl isosorbide, acetone, dimethylformamide, 1,4-dioxane, ethyl acetate, propyl acetate, polyethylene glycol, polyethylene glycol esters, polyethylene glycol sorbitans, polyethylene glycol monoalkyl ethers, polypolypropylene glycol, polypropylene alginate, polypolypropylene glycol-10 butanediol, polypolypropylene glycol-10 methyl glucose ether, polypolypropylene glycol-20 methyl glucose ether, polypolypropylene glycol-15 stearyl ether, polypolypropylene glycol dicaprylate, polypropylene glycol dicaprate, polypropylene glycol laurate; (ii) mixing the solution with the second solvent to define a pre-suspension; and (iii) adding energy to the pre-suspension to form particles having an average effective particle size of less than about 2 micron, and said adding energy step comprises homogenization, counter-current flow homogenization, microfluidization or sonication.
-
-
-
-
-
-
-
-
-
Search Results
35
records
(took 0.018 seconds)
